Overview

Efficacy Trial of Zonisamide for Myoclonus Dystonia

Status:
Completed
Trial end date:
2014-07-01
Target enrollment:
Participant gender:
Summary
Myoclonus Dystonia is a disease in which myoclonus distort the precision of movements and so cause a handicap in the movements of the everyday life. Response to oral medications may be incomplete and surgery may cause operating risk. Zonisamide is an antiepileptic drug which could bring a therapeutic profit in Myoclonus Dystonia on the severity of the myoclonus.
Phase:
Phase 3
Details
Lead Sponsor:
Assistance Publique - Hôpitaux de Paris
Treatments:
Zonisamide